Short-course High-dose Liposomal Amphotericin B for Human Immunodeficiency Virus–associated Cryptococcal Meningitis: A Phase 2 Randomized Controlled Trial
Author(s) -
Joseph N Jarvis,
Tshepo Leeme,
Mooketsi Molefi,
Awilly A Chofle,
Gabriella Bidwell,
Katlego Tsholo,
Nametso Tlhako,
Norah Mawoko,
Raju K K Patel,
Mark W. Tenforde,
Charles Muthoga,
Gregory P. Bisson,
Kidola Jeremiah,
John Changalucha,
David S. Lawrence,
Shabbar Jaffar,
William Hope,
Síle F. Molloy,
Thomas S. Harrison
Publication year - 2018
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/ciy515
Subject(s) - medicine , amphotericin b , confidence interval , cryptococcal meningitis , clinical endpoint , randomized controlled trial , fluconazole , meningitis , dose , human immunodeficiency virus (hiv) , gastroenterology , surgery , immunology , antifungal , viral disease , dermatology
We performed a phase 2 noninferiority trial examining the early fungicidal activity (EFA) of 3 short-course, high-dose liposomal amphotericin B (L-AmB) regimens for cryptococcal meningitis (CM) in Tanzania and Botswana.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom